Scholarlink

<p>It is predicted that by 2045, diabetes will affect approximately 700&#xa0;million individuals worldwide with increased morbidity, mortality and healthcare costs. Diabetes results in both microvascular and macrovascular complications, resulting in end-organ damage of blindness, renal failure, neuropathy and amputations, and increased cardiovascular disease, resulting in an enhanced mortality rate. The pathophysiology of diabetic complications involves the development of advanced glycation end products (AGEs) through nonenzymatic glycation interactions with proteins and nucleic acids, which is exacerbated by the persistent hyperglycemic state in type 2 diabetes mellitus. A key player in this process is the cellular receptor for AGEs, known as RAGE. AGEs activate RAGE by initiating various signalling pathways that contribute to increased oxidative stress and inflammation. These detrimental effects include impaired insulin signalling, disruption of metabolic homeostasis, toxicity to pancreatic beta cells, and epigenetic changes. To address diabetes glycemic control and its associated complications, several classes of drugs have been introduced to the market. Among them are GLP-1 agonists, DPP-4 inhibitors, and SGLT2 inhibitors. These medications employ different mechanisms of action to achieve glycemic control and have additional benefits. One such mechanism involves targeting the AGE/RAGE pathway, which reduces oxidative stress and inflammation by decreasing the formation of AGEs and suppressing RAGE expression in various organs. This approach shows potential in improving diabetes management and mitigating its resultant diabetes-related complications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The effects of DPP4 inhibitors, SGLT2 inhibitors and GLP1-RA on the AGE/RAGE pathway: implications for diabetes and its complications

  • 期刊论文

  • 发表日期：

    2025年10月14日

查看全文
  • Sajad Abolfazli,
  • Stephen L. Atkin,
  • Tannaz Jamialahmadi,
  • Amirhossein Sahebkar

摘要

It is predicted that by 2045, diabetes will affect approximately 700 million individuals worldwide with increased morbidity, mortality and healthcare costs. Diabetes results in both microvascular and macrovascular complications, resulting in end-organ damage of blindness, renal failure, neuropathy and amputations, and increased cardiovascular disease, resulting in an enhanced mortality rate. The pathophysiology of diabetic complications involves the development of advanced glycation end products (AGEs) through nonenzymatic glycation interactions with proteins and nucleic acids, which is exacerbated by the persistent hyperglycemic state in type 2 diabetes mellitus. A key player in this process is the cellular receptor for AGEs, known as RAGE. AGEs activate RAGE by initiating various signalling pathways that contribute to increased oxidative stress and inflammation. These detrimental effects include impaired insulin signalling, disruption of metabolic homeostasis, toxicity to pancreatic beta cells, and epigenetic changes. To address diabetes glycemic control and its associated complications, several classes of drugs have been introduced to the market. Among them are GLP-1 agonists, DPP-4 inhibitors, and SGLT2 inhibitors. These medications employ different mechanisms of action to achieve glycemic control and have additional benefits. One such mechanism involves targeting the AGE/RAGE pathway, which reduces oxidative stress and inflammation by decreasing the formation of AGEs and suppressing RAGE expression in various organs. This approach shows potential in improving diabetes management and mitigating its resultant diabetes-related complications.